Understand the source comparison
Selank Amidate PTSD Research Mechanism: Research Model Comparison
Rodent conditioned fear 0.3–1.0 mg/kg intranasal Fear extinction retention (% freezing reduction) GABA-A alpha-2 subunit upregulation in hippocampus CA1 Randomised, placebo-controlled Rodent chronic stress 0.5 mg/kg daily × 14 days Corticosterone AUC, open-fie
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent conditioned fear
- 0.3–1.0 mg/kg intranasal
- Fear extinction retention (% freezing reduction)
- GABA-A alpha-2 subunit upregulation in hippocampus CA1
- Randomised, placebo-controlled
- Rodent chronic stress
- 0.5 mg/kg daily × 14 days
- Corticosterone AUC, open-field anxiety behaviour
- Beta-endorphin stabilisation, HPA axis suppression
- Longitudinal cohort
- Human healthy volunteers
- 9 mg/day intranasal × 14 days
- STAI score reduction, cortisol response to social stress
- Presumed GABA-A modulation (receptor assays not feasible in humans)
- Double-blind, placebo-controlled crossover
- In vitro receptor binding
- 10–100 nM peptide concentration
- Alpha-2 subunit gene expression (qPCR)
- Direct GABA-A receptor transcription upregulation
- Cell culture (rat cortical neurons)
- Professional Assessment
- Standard Selank achieves measurable anxiolytic effects in 20–40 minutes but requires multiple daily dosing. Amidate formulations extend this window to 90–120 minutes, allowing twice-daily administration with sustained receptor engagement. For research into trauma memory reconsolidation. Where timing of intervention relative to memory reactivation is critical. The extended half-life offers a pharmacokinetic advantage standard Selank cannot match.